Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).

"Transparency declarations: J.St. has received research grants by the Ministry of Education and Research (BMBF) and Basilea Pharmaceuticals Inc.; has received speaker honoraria by Pfizer Inc., Gilead and Abbvie; has been a consultant to Gilead, Produkt&Markt GmbH, Alvea Vax. and Micron Research, and has received travel grants by German Society for Infectious Diseases (DGI e.V.) and Meta-Alexander Foundation. S.C.M. has received research support from Deutsches Zentrum für Infektionsforschung and Octapharma, has received consulting fees from Octapharma and has received travel grants from Gilead. Y.K. has licences with Elsevier, has received speaker honoraria from MSD Merck Sharp & Dohme, Ferring, Gilead Sciences, has received travel grants from Gilead Sciences, ViiV Healthcare and has participated on the data safety monitoring board of Gilead Sciences, ViiV Healthcare, MSD Merck Sharp & Dohme. R.S. has received speaker honoraria by Pfizer. A.Y.C. has no relevant conflicts of interest with regard to the topic of this guideline. M.H. has received research funding from MSD, Astellas, Pfizer, Scynexis, F2G, Euroimmun, Mundipharma, Gilead and NIH. R.K. received research grants from Merck and Pfizer and received speaker honoraria from Pfizer, Gilead, Astellas, Basilea, Merck, Angelini and Shionogi. M.S.H. has received travel grant from the German Society of Haematology and Medical Oncology (DGHO). W.J.H. has received lecture honoraria from Abbvie, Amgen, AstraZeneca, Celgene/Bristol-Myers Squibb, Gliead Sciences, Janssen, MSD Sharp & Dohme, Pfizer; has received support to attend meetings and travel support from Abbvie, Alexion, Astellas, Janssen, Lilly, MSD Sharp & Dohme, Novartis and Pfizer; and has participated on advisory boards from Abbvie, Amgen, AstraZeneca, Basilea, Celgene/BMS, Gliead Sciences, Janssen and Sanofi-Aventis. P.K. reports grants or contracts from German Federal Ministry of Research and Education (BMBF) B-FAST (Bundesweites Forschungsnetz Angewandte Surveillance und Testung) and NAPKON (Nationales Pandemie Kohorten Netz, German National Pandemic Cohort Network) of the Network University Medicine (NUM) and the State of North Rhine-Westphalia; Consulting fees Ambu GmbH, Gilead Sciences, Mundipharma Resarch Limited, Noxxon N.V. and Pfizer Pharma; Honoraria for lectures from Akademie für Infektionsmedizin e.V., Ambu GmbH, Astellas Pharma, BioRad Laboratories Inc., European Confederation of Medical Mycology, Gilead Sciences, GPR Academy Ruesselsheim, HELIOS Kliniken GmbH, Lahn-Dill-Kliniken GmbH, medupdate GmbH, MedMedia, MSD Sharp & Dohme GmbH, Pfizer Pharma GmbH, Scilink Comunicación Científica SC and University Hospital and LMU Munich; Participation on an Advisory Board from Ambu GmbH, Gilead Sciences, Mundipharma Resarch Limited and Pfizer Pharma; A pending patent currently reviewed at the German Patent and Trade Mark Office; Other non-financial interests from Elsevier, Wiley and Taylor & Francis online outside the submitted work. M.Ko. has no relevant conflicts of interest with regard to the topic of this guideline. O.P. has received honoraria or travel support from Gilead, Jazz, MSD, Novartis, Pfizer and Therakos; has received research support from Incyte and Priothera; is member of advisory boards to Equillium Bio, Jazz, Gilead, Novartis, MSD, Omeros, Priothera, Shionogi and SOBI. G.M. accepted honoraria for lectures from Gilead, Bristol-Myers Squibb, Merck-Serono, AMGEN, AstraZeneca and Janssen-Cilag and a travel grant from Janssen-Cilag. E.S. received speaker honoraria from Gilead. C.L.F. reports grants, personal fees and other from Gilead Sciences, grants and other from Astellas Pharma, personal fees from Pfizer, personal fees from Merck Sharp and Dohme, personal fees from bioMérieux, personal fees from F2G and personal fees from Immy, outside the submitted work. M.Ka. has received lecture Honoria from Gilead. M.R. has received consulting fees from Mundipharma and speaker honoraria from Novartis and Gilead. O.A.C. reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Abbvie, Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, IQVIA, Janssen, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, Pardes, Pfizer, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, Abbvie, Al-Jazeera Pharmaceuticals, Astellas, Gilead, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Noscendo, Pfizer, Shionogi; Payment for expert testimony from Cidara; Participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Janssen, MedPace, Paratek, PSI, Pulmocide, Shionogi, The Prime Meridian Group; A patent at the German Patent and Trade Mark Office (DE 10 2021 113 007.7); Stocks from CoRe Consulting; Other interests from DGHO, DGI, ECMM, ISHAM, MSG-ERC and Wiley. D.T. has received research grants by Gilead; has received speaker honoraria by Gilead, MSD and Pfizer; has been a consultant to Gilead, and MSD and has received travel grants by Astellas, the German Society for Haematology and Medical Oncology (DGHO), Gilead and the Paul Ehrlich Society (PEG). All other authors declare no conflict of interest."

"Funding This work was carried out as part of our routine duties and within our voluntary work for the German Society of Haematology and Oncology and did not receive any additional funding."